Melphalan flufenamide (multiple myeloma, ≥ 3 prior therapies, in combination with dexamethasone)

Subject:

• Active Substance: Melphalan flufenamide 
• Name: Pepaxti®
• Therapeutic area: Multiple myeloma
• Pharmaceutical company: Oncopeptides AB

Time table:

• Start: 01.10.2022
• Final decision by G-BA: 16.03.2023

Final decision:

• No additional benefit proved